A longer, sequential chemotherapy regimen offers better outcomes than two standard concurrent regimens for the treatment of early-stage, hormone sensitive breast cancer, according to research published in the the New England Journal of Medicine. Here is some information about breast cancer: ? It is the most common form of cancer in women ? Some types of breast cancer are sensitive to, and are thus be fed by, female hormones ? Treatments include surgery, chemotherapy, radiation, and drugs that block hormones Researchers from the Washington Hospital Center randomly assigned over 5000 women with early-stage breast cancer that was hormone sensitive to one of three chemotherapy regimens involving three drugs that are known together as ACT. The first group received the two drugs doxorubicin and cyclophosphamide followed by docetaxel. The second received doxorubicin and docetaxel together, and the third received doxorubicin, cyclophosphamide, and docetaxel together. After a follow-up of more than six years, a greater proportion of the women who received the sequential therapy were alive, as compared with those who received the doxorubicin and docetaxel regimen. After eight years, a greater proportion of women who received sequential therapy were both alive and cancer-free, as compared with the women in either of the other two treatment groups. In all three treatment groups, women who stopped menstruating for at least six months, a sign that their female hormones had successfully ? ?
See original here:
Breast Cancer Survival and Loss of Period ? In Depth
Source: http://www.breastcancerinfo.us/breast-cancer-survival-and-loss-of-period-in-depth/
country music awards autism awareness angelman syndrome total recall troy tulowitzki katie couric good morning america the rock vs john cena
কোন মন্তব্য নেই:
একটি মন্তব্য পোস্ট করুন